VERACYTE, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
VERACYTE, INC. (VCYT) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$62.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-07-31
- VERACYTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$99.38M.
- VERACYTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$52.94M.
- VERACYTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$6.95M, a 129.47% decline year-over-year.
- VERACYTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $23.59M.
- VERACYTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $122.88M, a 417.92% increase from fiscal 2024.
- VERACYTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $23.73M, a 61.84% decline from fiscal 2023.
- VERACYTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $62.17M.
- VERACYTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$18.36M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$62.95M 10-Q · filed 2026-07-31 | |||
| 2026-03-31 | -$99.38M 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $122.88M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $75.87M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | -$20.13M 10-Q · filed 2026-07-31 | |||
| 2025-03-31 | -$52.94M 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | $23.73M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $57.85M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $19.84M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$6.95M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $62.17M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $48.47M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $36.99M 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | $23.59M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$18.36M 10-K · filed 2025-02-28 | |||
| 2022-09-30 | -$1.76M 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | -$19.08M 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | -$9.34M 10-Q · filed 2023-05-05 | |||
| 2021-12-31 | -$174.51M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | -$183.51M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | -$19.88M 10-Q · filed 2022-08-03 | |||
| 2021-03-31 | -$25.16M 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | $190.05M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $185.76M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | -$11.87M 10-Q · filed 2021-07-29 | |||
| 2019-12-31 | $81.32M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |